Antimicrobial resistance (AMR) among bacterial pathogens is a silent pandemic and an urgent global public health threat. These superbugs, which are able to resist multiple antibiotics, are on the rise and have claimed millions of lives worldwide as well as long-term disabilities, and high economic costs associated with the healthcare burden.
According to a study by the Global Research on Antimicrobial Resistance (GRAM) Project published in the Lancet, 33 common bacterial infections were either directly or indirectly responsible for 7.7 million deaths in 2019. MRSA, an infection that primarily occurs in people who’ve been in hospitals or other healthcare settings, alone caused more than 100,000 deaths in 2019. These bacterial pathogens are deadlier than most better monitored pathogens such as malaria, HIV or tuberculosis.
The overuse and misuse of antibiotics have led to the emergence of AMR, which is a complex problem that requires a multi-pronged approach to address. The annual AMR death toll is expected to double by 2050 without sufficient intervention.
Environmental sustainability
The constant presence of antimicrobials in our environment increases the spread of AMR driven by the environmental impacts of the manufacture, use and disposal of antimicrobials. In both livestock and humans between 40 and 90 per cent of an antibiotic dose administered is excreted in faeces or urine. In agriculture, these excretes frequently reach the environment and are contaminating soil, plants and water. Pharmaceutical effluent discharge from manufacturing sites have also shown contamination often greater than those of agriculture and humans.
Diese Geschichte stammt aus der July 2023-Ausgabe von BioSpectrum Asia.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent ? Anmelden
Diese Geschichte stammt aus der July 2023-Ausgabe von BioSpectrum Asia.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent? Anmelden
Australia invests $1.89B for health and medical research transformation
The government is investing in a once in a generation transformation of health and medical research in Australia.
NZ suggests new way to prevent rheumatic heart disease progression
A new way of delivering treatment to prevent rheumatic heart disease progression is significantly less painful than an almost 70-year-old existing treatment, a University of Otago-led study in New Zealand (NZ) has found.
WHO prequalifies Takeda's dengue vaccine
A new vaccine for dengue has received prequalification from the World Health Organization (WHO).
GIBF invests $10M in Israel's Nectin Therapeutics to advance ADCs
Guangzhou-Israel Biotechnology Fund (GIBF) has invested $10 million in Nectin Therapeutics.
HOYA Group to distribute AIassisted lesion detection device in US
Japan-based HOYA Group Company, PENTAX of America, Inc. (PENTAX Medical, a division of HOYA Group) and MAGENTIQ-EYE, an artificial intelligence (AI)-based medical device company, have announced their intention to form a partnership in the field of AI in gastroenterology and to examine further collaboration and strategic partnerships.
Saudi Arabia pledges $500M to protect children from polio
At the first-ever World Economic Forum (WEF) Special Meeting hosted in Riyadh recently, the Kingdom of Saudi Arabia has pledged $500 million over the next five years to support the work of the Global Polio Eradication Initiative (GPEI).
Scientists explore use of COVID-19 variant vaccine against other coronaviruses
An international consortium of researchers developing a vaccine against troublesome COVID-19 variants will receive additional CEPI funding to investigate whether it could also protect against other deadly coronaviruses.
How Thai Biotech is Thriving with Innovations
Thailand's biotech industry is rapidly evolving, positioning itself as a key player in the ASEAN regions and the global biotechnology landscape. With a strategic focus on research and development, supportive government policies and a burgeoning ecosystem of startups and research institutions, Thailand is emerging as a hotspot for biotech innovation in Southeast Asia.
Why multi-use real estate is in demand for life sciences companies
India's Biocon, Enzene Biosciences, and Meteoric Biopharmacueticals, Japan's Daiichi Sankyo, and Singapore's Hummingbird Bioscience, have all recently sought to lease, acquire, and set up shop in a mixed-use space in the US. And for those companies who wish to enter or expand in the US market, New Jersey is a top choice due to its existing infrastructure, cultural connections, robust talent and location.
"The dialogue surrounding pharmaceutical gowning is experiencing significant transformation in 2024 & beyond"
Finland-based Lindström, a leading global provider of workwear, cleanroom workwear, and mat services, is making significant strides in its expansion efforts, particularly in key markets such as India, China, Vietnam, and Turkey.